What is the recommended diagnostic workup and treatment plan for a patient with suspected multiple system atrophy (MSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Multiple System Atrophy: Diagnostic Workup and Treatment

Diagnostic Workup

Start with MRI brain as your primary imaging modality to evaluate for characteristic patterns of regional atrophy, followed by ioflupane (DaTscan) SPECT/CT to confirm dopaminergic depletion and exclude essential tremor or drug-induced parkinsonism 1.

Clinical Diagnosis Framework

Apply the Movement Disorder Society (MDS) Criteria which now includes four diagnostic certainty levels: neuropathologically established MSA, clinically established MSA, clinically probable MSA, and possible prodromal MSA 2, 3. These updated criteria specifically aim to reduce time to diagnosis compared to older consensus statements.

Key Clinical Features to Identify

Look for the combination of:

  • Autonomic failure: Orthostatic hypotension (≥30 mmHg systolic or ≥15 mmHg diastolic drop), urinary incontinence or retention, erectile dysfunction, anhidrosis
  • Motor symptoms: Either parkinsonian features (MSA-P subtype) or cerebellar ataxia (MSA-C subtype)
  • Age of onset: Typically 55-65 years
  • Disease progression: Mean duration approximately 6 years 1

Imaging Algorithm

  1. MRI Brain (First-line): Demonstrates regional volume loss patterns characteristic of MSA. Look for putaminal atrophy, "hot cross bun" sign in the pons (MSA-C), and middle cerebellar peduncle abnormalities 1.

  2. Ioflupane I-123 SPECT/CT (DaTscan): Shows abnormal dopaminergic depletion in MSA, PSP, CBD, and PD—but critically a normal scan excludes parkinsonian syndromes 1. This differentiates MSA from essential tremor and drug-induced tremor early in disease course.

  3. Avoid CT head: Limited soft-tissue characterization makes it inferior to MRI 1.

  4. FDG-PET/CT: Limited evidence for routine use; may show hypometabolism patterns but not first-line 1.

Ancillary Testing

Perform comprehensive autonomic testing including:

  • Lying and standing blood pressure measurements to document orthostatic hypotension 4, 5
  • Cardiovascular autonomic function tests
  • Urological evaluation for bladder dysfunction
  • Sleep study (evaluate for REM sleep behavior disorder)
  • Olfactory testing (typically preserved in MSA, unlike PD)
  • Dysphagia assessment 4

Common Pitfall: Do not rely on clinical features alone—imaging is essential as MSA mimics other conditions, particularly early Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration 1, 4.

Treatment Plan

There is no disease-modifying therapy for MSA; focus treatment on the patient's most disabling symptoms, prioritizing autonomic dysfunction management first, then motor symptoms 6, 7.

Autonomic Symptom Management (Priority #1)

Orthostatic Hypotension:

  • Non-pharmacological first: Increase salt and fluid intake, elevate head of bed 30 degrees, compression stockings, avoid aggravating factors (large meals, warm environments, rapid position changes) 5
  • Pharmacological: Fludrocortisone, midodrine, or droxidopa when symptomatic hypotension persists 7, 5

Urinary Dysfunction:

  • For retention: Intermittent self-catheterization
  • For incontinence: Anticholinergics (but monitor for cognitive effects and worsening constipation) 7, 5

Constipation: Polyethylene glycol, increased fiber, adequate hydration 7

Erectile Dysfunction: Sildenafil (but monitor blood pressure carefully given orthostatic hypotension risk) 5

Motor Symptom Management (Priority #2)

Parkinsonian Features:

  • Trial levodopa/carbidopa: Despite conventional teaching, 40-60% of MSA-P patients show some response to levodopa 5. Start with adequate doses (up to 1000-1200 mg/day) for at least 3 months before declaring treatment failure 6, 7.
  • Dopamine agonists or amantadine are alternatives but not more effective than levodopa 5

Cerebellar Ataxia:

  • No effective pharmacological treatment
  • Focus on physical therapy, gait training, assistive devices 7

Critical Balancing Act: Antiparkinsonian medications may worsen orthostatic hypotension. Titrate carefully and prioritize which symptom is most disabling to quality of life 7, 5.

Multidisciplinary Team Approach

Coordinate care between:

  • Neurology (movement disorders specialist)
  • Autonomic specialists
  • Urology
  • Physical/occupational therapy
  • Speech therapy (for dysarthria and dysphagia)
  • Primary care for overall coordination 7

Prognosis Counseling: Mean disease duration is approximately 6 years from onset; patients and families need early palliative care discussions 1.

References

Guideline

acr appropriateness criteria® movement disorders and neurodegenerative diseases.

Journal of the American College of Radiology, 2020

Research

Multiple system atrophy.

Practical neurology, 2023

Research

Diagnosis of multiple system atrophy.

Autonomic neuroscience : basic & clinical, 2018

Research

Management of multiple system atrophy: state of the art.

Journal of neural transmission (Vienna, Austria : 1996), 2005

Research

Multiple system atrophy: current and future approaches to management.

Therapeutic advances in neurological disorders, 2010

Research

My Treatment Approach to Multiple System Atrophy.

Mayo Clinic proceedings, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.